Endocrinology, Vol 132, 577-583, Copyright © 1993 by Endocrine Society

ARTICLES

The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites

BT Zhu, D Roy and JG Liehr
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston 77555-1031.

Estrogens induce kidney tumors in Syrian hamsters. The mechanism of carcinogenesis is unknown and has been investigated in this study using a weak carcinogen, 17 alpha-ethinyl estradiol (EE), and a strongly carcinogenic estrogen, 17 alpha-ethinyl-11 beta-methoxyestradiol [moxestrol (MOX)]. We investigated rates of conversion of estrogens to catechol metabolites and rates of their methylation to methyl ethers in order to examine the hypothesis that catechol metabolites mediate estrogen-induced carcinogenesis. Rates of conversion of MOX to catechol metabolites by hamster liver or kidney cortex microsomes were 40-50% of those with estradiol as substrate. However, the rate of catechol-O- methyltransferase-catalyzed methylation of 2-hydroxy-MOX was the least of the catechol metabolites examined when incubated with cytosol of hamster kidney. In contrast, EE was converted to catechol metabolites by hamster liver and kidney microsomes at rates 25-35% of those obtained with estradiol. These catechol metabolites of EE were methylated by catechol-O-methyltransferase of hamster kidney cytosol at rates slightly lower than those observed with catechols of estradiol. The progesterone receptor binding of EE and MOX was investigated, because progesterone is known to inhibit estrogen-induced carcinogenesis in the hamster kidney. Neither estradiol nor MOX inhibited the binding of progesterone to its receptor in hamster kidney cytosol. However, in the presence of 20 nM EE, the binding affinity of radiolabeled progesterone to receptor was inhibited (increase in Kd from 0.98 nM in controls to 3.02 nM in the presence of EE). Maximum binding values (5.0 fmol/mg protein in controls and 6.0 fmol/mg protein in the presence of EE) were not significantly altered. These results support the hypothesis that estrogen-induced carcinogenesis is mediated by catechol estrogen metabolites. The carcinogenic estrogen MOX is converted to catechol metabolites at lower rates than estradiol, but their methylation may be sterically hindered by the 11 beta-methoxy substituent. In contrast, the rates of conversion of the weakly carcinogenic EE to catechol metabolites are low, whereas their methylation rates are only marginally lower than those of 2- and 4- hydroxyestradiol. The decreased capacity of EE to form catechol metabolites in conjunction with its partial progestin agonist activity in the target organ of hamsters may contribute to the low tumor incidence.

This article has been cited by other articles:

				J. H. Fowke, X.-O. Shu, Q. Dai, F. Jin, Q. Cai, Y.-T. Gao, and W. Zheng Oral Contraceptive Use and Breast Cancer Risk: Modification by NAD(P)H:Quinone Oxoreductase (NQO1) Genetic Polymorphisms Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1308 - 1315. [Abstract] [Full Text] [PDF]

				M. Sasaki, M. Kaneuchi, N. Sakuragi, and R. Dahiya Multiple Promoters of Catechol-O-methyltransferase Gene Are Selectively Inactivated by CpG Hypermethylation in Endometrial Cancer Cancer Res., June 15, 2003; 63(12): 3101 - 3106. [Abstract] [Full Text] [PDF]

				H. K. Bhat, G. Calaf, T. K. Hei, T. Loya, and J. V. Vadgama Critical role of oxidative stress in estrogen-induced carcinogenesis PNAS, April 1, 2003; 100(7): 3913 - 3918. [Abstract] [Full Text] [PDF]

				A. J. Lee, J. W. Kosh, A. H. Conney, and B. T. Zhu Characterization of the NADPH-Dependent Metabolism of 17beta -Estradiol to Multiple Metabolites by Human Liver Microsomes and Selectively Expressed Human Cytochrome P450 3A4 and 3A5 J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 420 - 432. [Abstract] [Full Text] [PDF]

				E. Cavalieri, K. Frenkel, J. G. Liehr, E. Rogan, and D. Roy Chapter 4: Estrogens as Endogenous Genotoxic Agents--DNA Adducts and Mutations J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 75 - 94. [Abstract] [Full Text] [PDF]

				C. R. Jefcoate, J. G. Liehr, R. J. Santen, T. R. Sutter, J. D. Yager, W. Yue, S. J. Santner, R. Tekmal, L. Demers, R. Pauley, et al. Chapter 5: Tissue-Specific Synthesis and Oxidative Metabolism of Estrogens J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 95 - 112. [Abstract] [Full Text] [PDF]

				J. G. Liehr Is Estradiol a Genotoxic Mutagenic Carcinogen? Endocr. Rev., February 1, 2000; 21(1): 40 - 54. [Abstract] [Full Text]

				R. R. Newbold and J. G. Liehr Induction of Uterine Adenocarcinoma in CD-1 Mice by Catechol Estrogens Cancer Res., January 1, 2000; 60(2): 235 - 237. [Abstract] [Full Text]

				P. T. Mannisto and S. Kaakkola Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors Pharmacol. Rev., December 1, 1999; 51(4): 593 - 628. [Abstract] [Full Text] [PDF]